An article in Psychiatry Advisory states that the long-acting, injectable antipsychotic called Invega Sustenna is effective in treating Schizophrenia for a longer amount of time than the commonly prescribed oral antipsychotics. Invega Sustenna is administered once a month and has been found to delay relapse for up to six months longer than oral antipsychotics. Long-acting antipsychotics have the potential to provide an added benefit over oral antipsychotics, as they not only prevent relapse longer but also improve patient adherence. To read this article in its entirety, click here.